Filter
Sort
Tuberculosis (TB) is the world’s second leading infectious disease killer after COVID-19. Drug resistance to TB is a public health crisis. ISB researchers have developed algorithms to predict the efficacy of drugs in treating Mycobacterium tuberculosis (MTB), the causative agent for TB. These research findings were published in the journal Cell Reports Methods.
In the final ISB-Town Hall Seattle Science Series of 2021, ISB Assistant Professor Dr. Sean Gibbons sat down with UCSD Professor Dr. Jack Gilbert, and the two microbiome experts discussed past research, exciting science happening today, promising products and therapies on the horizon, and much more.
More than 300 people registered for Reimagine: Your Immune System, ISB’s annual virtual fundraiser, for an evening that included guest appearances Nobel laureate Dr. David Baltimore, immunology expert Dr. Mark Davis, ISB President Dr. Jim Heath, and a host of ISB researchers studying the human immune system.
The 2021 ISB Virtual Microbiome Series highlighted recent advances toward understanding general patterns of commensal population genomic variation within the human gut, how fine-scale commensal genomic variation is influenced by host phenotypic variation, and whether or not commensal genomic variation has an impact on human health and disease.
Longevity and aging researcher Dr. Nir Barzilai participated in a fireside chat conversation with ISB Co-founder and Professor Dr. Lee Hood. The two renowned scientists talked about Barzilai’s study of 750 centenarians, how aging research has changed over the years, and what exciting developments are coming.
By taking detailed measurements of blood and other biological samples, ISB scientists have shown they can identify markers for cancer years before diagnosis. This was the topic of a recent Research Roundtable presentation delivered by Dr. Andrew Magis, Director of Data Science in ISB’s Health Data Science Lab.